ClinVar Miner

Submissions for variant NM_000059.4(BRCA2):c.1682G>T (p.Gly561Val)

dbSNP: rs1593893593
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV000804687 SCV000944607 uncertain significance Hereditary breast ovarian cancer syndrome 2018-07-26 criteria provided, single submitter clinical testing This variant is not present in population databases (ExAC no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with BRCA2-related disease. This sequence change replaces glycine with valine at codon 561 of the BRCA2 protein (p.Gly561Val). The glycine residue is moderately conserved and there is a moderate physicochemical difference between glycine and valine.
Ambry Genetics RCV002397634 SCV002711013 uncertain significance Hereditary cancer-predisposing syndrome 2023-11-18 criteria provided, single submitter clinical testing The p.G561V variant (also known as c.1682G>T), located in coding exon 9 of the BRCA2 gene, results from a G to T substitution at nucleotide position 1682. The glycine at codon 561 is replaced by valine, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
University of Washington Department of Laboratory Medicine, University of Washington RCV002397634 SCV003851572 likely benign Hereditary cancer-predisposing syndrome 2023-03-23 criteria provided, single submitter curation Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.